Renishaw has announced that Boston Children’s Hospital (BCH) has become the latest world leading health organization in the U.S. to have a neuromate stereotactic robot installed.
BCH hosts a National Association of Epilepsy Centres (NAEC) accredited Level 4 Epilepsy Centre, and the team plans to begin integrating their newly installed neuromate into their Stereoelectroencephalography (SEEG) procedures. The neuromate’s role will be to assist in positioning the intracerebral electrodes which identify the epileptogenic zone. The robotic system integrates with BCH’s existing stereotactic neurosurgery infrastructure for reduced procedure times and enhanced surgical capabilities.
“The addition of the neuromate system to our workflow promises to significantly increase the efficiency of our stereotactic surgeries, lower the risk for human error in targeting, and complements other neurosurgical technologies that together allows us to stay at the cutting edge of paediatric neurosurgical therapies,” said Dr. Scellig Stone, Director of Stereotactic and Functional Neurosurgery at BCH, as well as an Assistant Professor at Harvard University.
The neuromate stereotactic robot is designed to provide a consistent, accurate and repeatable platform during a broad range of stereotactic neurosurgical procedures. Through accurate positioning of the neuromate’s robotic arm, neurosurgeons can be confident of reaching structures deep within the brain safely.
Dr Abed Hammoud, CEO of Renishaw Mayfield SA (Switzerland) said, “We are excited and proud that Boston Children’s Hospital have chosen the neuromate to be an integral part of their workflow. Our service team will work closely with Dr. Scellig Stone and his team at this world class institution to address their needs as they continue to provide the best care for their patients.”